Axsome Therapeutics - AXSM Stock Forecast, Price & News

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics Trading Up 2.1 %

NASDAQ:AXSM traded up $0.95 on Friday, hitting $46.27. 597,361 shares of the stock were exchanged, compared to its average volume of 1,113,164. The company has a debt-to-equity ratio of 6.15, a quick ratio of 3.54 and a current ratio of 2.44. The stock has a fifty day moving average price of $36.27 and a two-hundred day moving average price of $33.63. The firm has a market capitalization of $1.80 billion, a P/E ratio of -11.80 and a beta of 1.92. Axsome Therapeutics has a 52-week low of $19.38 and a 52-week high of $48.82.

Axsome Therapeutics (NASDAQ:AXSM - Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.13. During the same quarter in the previous year, the business earned ($0.86) EPS. Research analysts forecast that Axsome Therapeutics will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AXSM shares. Mizuho dropped their price objective on shares of Axsome Therapeutics from $51.00 to $49.00 in a report on Tuesday, May 3rd. Cowen raised their target price on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 29th. Cantor Fitzgerald reduced their price objective on shares of Axsome Therapeutics from $64.00 to $54.00 in a research report on Wednesday. Cowen lifted their price objective on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a research report on Wednesday, June 29th. Finally, Morgan Stanley lifted their price objective on shares of Axsome Therapeutics from $54.00 to $55.00 and gave the company an "equal weight" rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $90.63.